OncoSignal
Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:21 UTC. Every row links to its source record.

Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time

Mirdametinib + BGB-3245 in Advanced Solid Tumors

NCT05580770 · SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · PHASE1/PHASE2 · terminated · last registry update 2026-08-20 · Decision brief

No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.

What was said, and by whom

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

KindQuoteOur categorySource
Stated“Lack of tolerability of BGB-3245 (Brimarafenib) when given in combination with Mirdametinib”–Registry record, SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Also happening at the time. Not shown to be a cause.

Registry events on other trials of drugs against MAP2K1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.

What is not public

  • Internal portfolio and board discussions
  • Unpublished trial data and interim analyses
  • Terms of any partner or licence decision